Pharming Group N.V annual gross margin
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Gross Margin Growth & History (PHAR)
Pharming Group N.V's gross margin was 87.90% for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 87.90% | −0.19 pp |
| 2024 | 2024-12-31 | 88.09% | −1.63 pp |
| 2023 | 2023-12-31 | 89.72% | −1.74 pp |
| 2022 | 2022-12-31 | 91.46% | +2.09 pp |
| 2021 | 2021-12-31 | 89.37% | +0.46 pp |
| 2020 | 2020-12-31 | 88.91% | +1.54 pp |
| 2019 | 2019-12-31 | 87.37% | — |
Pharming Group N.V gross margin trends
Over the last five fiscal years, Pharming Group N.V's gross margin decreased from 88.91% to 87.90%, a change of −1.00 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming secures priority review for lower-dose pediatric Joenja
Pharming ($PHAR) said the FDA accepted its supplemental application for a lower-dose Joenja formulation and granted priority review. The proposed expansion addresses patients aged four and older with activated PI3K delta syndrome who weigh ...
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...
